COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements

COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

 

AstraZeneca
Press Releases
New Vaxzevria data further support its use as third dose booster
13 January 2022
::New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with Vaxzevria
:: Additional analysis showed increased antibody response to Omicron after a third dose

Bharat Biotech
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias
13 de Enero, 2022
Más del 82% de la población cubana completó su esquema de vacunación.
[More than 82% of the Cuban population completed their vaccination schedule.]

12 de Enero, 2022
Abdala muestra una seroconversión superior al 98% en población pediátrica.
[Abdala shows a seroconversion greater than 98% in the pediatric population.]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases – No new digest announcements identified

 

Moderna
Press Releases – No new digest announcements identified

 

Novavax
Press Releases
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
Jan 12, 2022

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax’ COVID-19 Vaccine in South Africa
Jan 12, 2022

 

Pfizer
Recent Press Releases
01.12.2022
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released

01.10.2022
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
:: Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy
:: Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
11 January 2022 GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

 

Merck
News releases – No new digest announcements identified

 

Novartis
News
Media Release Jan 10, 2022
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

 

SK Biosciences
Press releases
SK bioscience Obtained Biologics License Application Approval of Novavax’ COVID-19 Vaccine in Korea
The first approval of a recombinant protein nanoparticle COVID-19 vaccine with proven efficacy and s…
2022. 01. 12

 

Valneva
Press Releases – No new digest announcements identified